» Articles » PMID: 35693614

Analysis of the Prognostic Role and Biological Characteristics of Circulating Tumor Cell-associated White Blood Cell Clusters in Non-small Cell Lung Cancer

Overview
Journal J Thorac Dis
Specialty Pulmonary Medicine
Date 2022 Jun 13
PMID 35693614
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Recently, circulating tumor-cell-associated white blood cell (CTC-WBC) clusters have been reported to have prognostic value in some cancers. The prognostic role of CTC-WBC clusters in lung cancer has not yet been elucidated. Very little information is available about the biological characteristics of CTC-WBC clusters.

Methods: A total of 82 patients with non-small cell lung cancer (NSCLC) were included in this study, and 61 patients with advanced-stage disease were closely followed-up. All patients had blood drawn prior to treatment. Subtraction enrichment and immunostaining-fluorescence hybridization (SE-iFISH) platform was used to isolate and identify CTCs and CTC-WBC clusters. Kaplan-Meier survival analysis and Cox regression analysis were applied to assess patient progression-free survival (PFS). Further, qualitative and quantitative analyses the size and ploidy characteristics of CTC-WBC clusters.

Results: Firstly, CTC-WBC clusters appeared more in the advanced (stage III and IV) stage (P=0.043) than in the early stage. Furthermore, the multivariable analysis (Cox proportional hazards model) revealed that the high-CTC (≥7/6 mL) group and CTC-WBC clusters (≥1/6 mL) positive group both had significantly worse PFS, with a hazard ratio (HR) of 2.89 [95% confidence interval (CI): 1.36-6.17, P=0.006] and 2.18 (95% CI: 1.07-4.43, P=0.031), respectively. In the conjoint analysis, compared to patients with <7 CTCs/6 mL without CTC-WBC clusters, patients with ≥7 CTCs/6 mL with CTC-WBC clusters had the highest risk of progression (HR =7.13, 95% CI: 2.51-20.23, P<0.001). In addition, the presence of ≥3-cell CTC-WBC clusters in patients may indicate a shorter PFS (P<0.05) and a higher risk of progression (HR =2.90, 95% CI: 1.06-7.89, P=0.037). Furthermore, compared with the characteristics of the total CTCs, almost all of the CTCs that could recruit WBCs were large cells (≥5 µm) and exhibited polyploidy (≥ tetraploid) (both P<0.01).

Conclusions: The presence of CTC-WBC clusters was an independent prognostic factor for advanced NSCLC. The joint analysis of CTCs and CTC-WBC clusters could provide additional prognostic value to the enumeration of CTCs alone. Besides, most of the CTCs in CTC-WBC clusters were large polyploid cells.

Citing Articles

Superhydrophobic Array Devices for the Enhanced Formation of 3D Cancer Models.

Lopez-Cavestany M, Wright O, Reckhorn N, Carter A, Jayawardana K, Nguyen T ACS Nano. 2024; 18(34):23637-23654.

PMID: 39150223 PMC: 11363216. DOI: 10.1021/acsnano.4c08132.


Research progress on the multi-omics and survival status of circulating tumor cells.

Xie Q, Liu S, Zhang S, Liao L, Xiao Z, Wang S Clin Exp Med. 2024; 24(1):49.

PMID: 38427120 PMC: 10907490. DOI: 10.1007/s10238-024-01309-z.


Prognostic value of circulating tumor cells associated with white blood cells in solid cancer: a systematic review and meta-analysis of 1471 patients with solid tumors.

Ju M, Gao Z, Gu G, Huang H, Sun A, Zheng C BMC Cancer. 2023; 23(1):1224.

PMID: 38087278 PMC: 10717563. DOI: 10.1186/s12885-023-11711-7.


CD47 Expression in Circulating Tumor Cells and Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor.

Torres J, Brito A, E Silva V, Messias I, Braun A, Ruano A Int J Mol Sci. 2023; 24(15).

PMID: 37569332 PMC: 10419161. DOI: 10.3390/ijms241511958.


Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.

Wang Y, Liu Y, Zhang Z, Lu B, Gao Y, Tong L BMC Cancer. 2023; 23(1):578.

PMID: 37349714 PMC: 10286386. DOI: 10.1186/s12885-023-10985-1.


References
1.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

2.
Mukaida N, Sasaki S, Baba T . Two-Faced Roles of Tumor-Associated Neutrophils in Cancer Development and Progression. Int J Mol Sci. 2020; 21(10). PMC: 7278934. DOI: 10.3390/ijms21103457. View

3.
El-Kenawi A, Hanggi K, Ruffell B . The Immune Microenvironment and Cancer Metastasis. Cold Spring Harb Perspect Med. 2019; 10(4). PMC: 7117953. DOI: 10.1101/cshperspect.a037424. View

4.
Luo Q, Wang C, Peng B, Pu X, Cai L, Liao H . Circulating Tumor-Cell-Associated White Blood Cell Clusters in Peripheral Blood Indicate Poor Prognosis in Patients With Hepatocellular Carcinoma. Front Oncol. 2020; 10:1758. PMC: 7667255. DOI: 10.3389/fonc.2020.01758. View

5.
Labelle M, Begum S, Hynes R . Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A. 2014; 111(30):E3053-61. PMC: 4121772. DOI: 10.1073/pnas.1411082111. View